Novartis’ Lucentis gets EU approval to treat pathologic myopia

The European Commission has approved Novartis’ Lucentis (ranibizumab) for the treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news